Study evaluates Mindray BC-75R Vet against Advia 2120i
Bottom line
Version 1
A new peer-reviewed validation study in the Journal of Veterinary Diagnostic Investigation evaluated the Mindray BC-75R Vet hematology analyzer in 411 dogs and 225 cats, comparing its complete blood count and reticulocyte results with the Siemens Advia 2120i, a long-used reference platform in veterinary clinical pathology. According to the study abstract and related conference materials from the University of Bologna team, the BC-75R Vet uses electrical impedance plus SF-Cube technology, which combines laser scatter, fluorescence, and 3D analysis, and was assessed for analytical performance, including repeatability and method comparison. The broader context matters here: the Advia platform remains widely used in veterinary reference settings and academic labs, including Cornell and independent veterinary laboratories, making it a meaningful benchmark for comparison. (vet.cornell.edu)
Why it matters: For veterinary professionals, another independently evaluated hematology platform could expand confidence in CBC workflow choices, especially for dog and cat samples where platelet counts, hemoglobin bias, reticulocyte analysis, and abnormal differentials can affect clinical interpretation. Prior veterinary literature has shown that most CBC measurands on hematology analyzers can perform acceptably, but platelet counts and some differential counts remain common trouble spots, and one meta-analysis specifically noted hemoglobin bias associated with the Advia 2120. That means validation studies like this are less about declaring a winner than about understanding where results align, where they diverge, and when smear review and nonstatistical quality control still matter. (pubmed.ncbi.nlm.nih.gov)
What to watch: Watch for the full paper’s final published details, including species-specific bias data, platelet and reticulocyte performance, and whether outside clinical pathologists publish independent follow-up comparisons. (esvcp2024.hu)
Key facts
- Study type
- Peer-reviewed validation study
- Journal
- Journal of Veterinary Diagnostic Investigation
- Analyzer
- Mindray BC-75R Vet hematology analyzer
- Comparator
- Siemens Advia 2120i
- Species
- Dogs and cats
- Sample size
- 411 dogs, 225 cats
- Technology
- Electrical impedance and SF-Cube technology
- Evaluated outputs
- Complete blood count and reticulocyte results
Version 2
A new study accepted in the Journal of Veterinary Diagnostic Investigation puts the Mindray BC-75R Vet hematology analyzer under a closer spotlight, comparing it with the Siemens Advia 2120i for use in dogs and cats. The paper, authored by researchers including Martina Baldin, Sabrina Fasoli, and Kateryna Vasylyeva, evaluated samples from 411 dogs and 225 cats submitted for routine testing, adding fresh data to a part of veterinary diagnostics where instrument-specific differences can directly shape how CBC results are interpreted. (futurlab.it)
The study lands in a familiar landscape for veterinary clinical pathology. The Advia 2120/2120i has been used for years as a comparator in veterinary hematology validation work and still appears in reference-lab and academic workflows. Cornell’s Animal Health Diagnostic Center describes its Advia analyzer as a tool for automated hemograms across multiple species, while Siemens highlights continued use of the ADVIA system in multispecies veterinary laboratory testing. That long-standing role helps explain why a comparison against the Advia still carries weight when a newer analyzer enters the conversation. (vet.cornell.edu)
Based on the abstract provided and preliminary conference reporting from the University of Bologna group, the BC-75R Vet combines electrical impedance with SF-Cube technology, integrating laser scatter, fluorescence, and three-dimensional analysis for CBC and reticulocyte testing. The earlier canine-focused conference abstract described validation work on precision, linearity, carryover, and accuracy against the Advia 2120i. The newly reported journal study expands that work to both dogs and cats and substantially increases the sample set, suggesting a more clinically relevant validation across routine case material rather than a narrow healthy-animal dataset. (esvcp2024.hu)
While the full article text was not readily accessible in search results, the surrounding literature gives a clear sense of what reviewers and laboratory directors will likely focus on. Veterinary hematology analyzer validation usually hinges on repeatability, bias at decision limits, agreement for platelet counts and differentials, and how results hold up in real-world samples with clumping, nucleated red blood cells, or other interferences. Prior meta-analyses in veterinary hematology have found that most CBC measurands perform acceptably across analyzers, but platelet counts and differential leukocyte results are more variable. One 2017 meta-analysis also flagged hemoglobin bias tied to the Advia 2120, which is important context when interpreting “agreement” with that instrument. (pubmed.ncbi.nlm.nih.gov)
There are also early signs of industry interest in the BC-75R Vet’s platelet and reticulocyte performance. A recent Mindray Animal Medical post, citing field experience from a laboratory user, said the analyzer showed improved coherence in hemoglobin-hematocrit relationships and helped address platelet aggregate interference in feline samples through a fluorescence platelet-counting mode. That is promotional material, not independent evidence, but it points to exactly the kinds of claims veterinary laboratorians will want to see tested in peer-reviewed datasets, especially in cats, where platelet clumping can complicate automated counts. (linkedin.com)
Why it matters: For veterinary professionals, this isn’t just another instrument paper. CBC data drive everyday decisions in general practice, emergency care, oncology, internal medicine, and transfusion workups, and small analytic differences can matter when a patient is near a treatment threshold. A validated alternative to a long-established reference platform could give laboratories and larger hospitals more flexibility in analyzer selection, but only if clinicians understand where equivalence is strong and where caution is still needed. The practical takeaway is the same one reinforced across prior validation studies: automated hematology is highly useful, but smear review, species-specific interpretation, and quality control remain essential, particularly for platelets, abnormal leukograms, and discordant hemoglobin or hematocrit findings. (vet.cornell.edu)
What to watch: The next step is the full publication record, including species-level performance tables and any stated limitations around platelet counts, reticulocytes, or abnormal samples. It will also be worth watching whether independent clinical pathology groups, reference labs, or residency programs replicate the findings outside the original research setting, because adoption decisions in veterinary diagnostics often depend as much on reproducibility and workflow fit as on headline correlation data. (esvcp2024.hu)